Medclair
CARE FOR FUTURE

Interim Report April–June 2026

Strong order intake paves the way for continued growth

Q2

The Group

The Group's income statement for the period January – June 2026 includes results from the parent company Medclair AB and the subsidiary Medclair Sweden AB.
The comparative period is January – June 2025.

First half 2026 in brief

- Order intake amounted to SEK 41.2 million (34,7)
- Net sales amounted to SEK 32.5 million (31,4)
- Profit before depreciation and financial items SEK 6.3 million (10.0)
- Profit after tax amounted to SEK 3.3 million (6,5)
- Earnings per share after tax amounted to SEK 0.04 (0.08)

1 April – 30 June 2026

- Order intake amounted to SEK 25.1 million (12.7)
- Net sales amounted to SEK 14.3 million (15.8)
- Profit before depreciation and financial items SEK 1.1 million (4.4)
- Profit after tax amounted to SEK -0.4 million (2.5)
- Earnings per share after tax amounted to SEK -0.005 (0.03)

Key figures (TSEK)	Q2 2026	Q2 2025	H1 2026	H1 2025	Full year 2025
Net sales	14,280	15,835	32,518	31,467	52,084
Order intake	25,100	12,700	41,200	34,700	73,200
Book-to-Bill Ratio	1.76	0.80	1.27	1.11	1.4
EBITDA	1,129	4,350	6,271	10,029	11,171
Earnings per share (SEK)	-0.005	0.03	0.04	0.08	0.06
Intangible fixed assets	34,679	33,740	34,679	33,740	33,817
Cash and cash equivalents	18,870	1,256	18,870	1,256	5,739
Cash flow	-1,502	-2,303	13,131	-1,327	3,156
Equity	78,734	55,529	78,734	55,529	53,686
Total assets	92,363	64,327	92,363	64,327	60,677
Equity ratio (%)	85%	86%	85%	86%	88%
Quick ratio / Current ratio (%)	384%	282%	384%	282%	306%
Number of shares at end of period	91,647,057	82,492,067	91,647,057	82,492,067	82,492,057
Number of employees end of period	21	15	21	15	16

Significant events during the second quarter

- **Medclair featured in French national media**
  Medclair is highlighted on TF1, one of France's largest TV channels, following a segment featuring customer Denat Environnement. The segment showcases Medclair's products for recycling customers, including Expo.p – the company's latest portable solution for measuring nitrous oxide exposure. This strengthens Medclair's visibility in France, a strategically important market.
- **Veolia chooses Medclair for nitrous oxide destruction in new market**
  Medclair AB has received a conditional order regarding a system solution for the destruction of nitrous oxide emissions from a company within the global environmental group Veolia. The deal, valued at approximately SEK 3.65 million, includes an installation for the destruction of nitrous oxide (N_2O) from gas cylinders within the recycling industry.
- **Medclair's technology enables compliance with strict new limit values – independent French study confirms results**
  An independent clinical evaluation at the Pierre Colson Burn Center in Lyon confirms that Medclair's Mobile Destruction Unit (MDU) is a critical prerequisite for healthcare providers to meet strict regulatory requirements for the working environment. The study, published in the scientific journal Anaesthesia, shows that Medclair's technology reduces nitrous oxide exposure to levels that ensure compliance with the latest national limit values.
- **Medclair Lowers Barriers to Global Billion-Scale Market – New Technology Accelerates Expansion and Strengthens Market Position**
  Medclair is approaching the launch of its next-generation system for the safe and sustainable use of nitrous oxide. The new platform is expected to become a central driver of the company's growth through increased scalability, a business model with a higher share of recurring revenue, and a greater competitive advantage. The total market for the company's solutions is estimated at SEK 17 billion, and Medclair's upcoming system is instrumental in increasing the addressable market.
- **Medclair strengthens its position in French recycling – new deals and increased demand**
  Medclair has signed an additional two orders within the recycling segment in France, to a total value of approximately 1.9 MSEK. The company has thereby established four customers within the French recycling sector – which strengthens Medclair's position among both private and municipal actors. Given the strong establishment, Medclair has now assumed a strategic position as a supplier of solutions for safe and sustainable nitrous oxide.
- **Medclair strengthens the organization with key expertise in marketing and finance**
  Medclair has appointed Anette Franzén as Head of Marketing and Sina Sharif as Head of Finance. These appointments bring key expertise in marketing, communications, investor relations, and financial management, and strengthen the company's foundation for continued international expansion, increased visibility, and long-term value creation.
- **The first order for mobile systems in Denmark demonstrates the strength of Medclair's growth model**
  Medclair has received an order for three mobile systems from Region Hovedstaden in Denmark. The customer already uses the company's central system, making the deal a clear example of Medclair's ability to generate growth through upselling and expansion with existing customers. With solutions installed or ordered at seven hospitals in Denmark, Medclair has established a strong foothold in a market where more than 20 hospitals use nitrous oxide, while significant growth opportunities exist within both healthcare and dentistry.
- **Medclair's Danish growth continues – secures order from a new region**
  Medclair has received an order worth just over 3 MSEK for nitrous oxide destruction systems. The deal entails establishing a presence with a new customer and creates the conditions for continued expansion within the region. The order strengthens the company's position in Denmark, a market where Medclair has grown strongly in recent years.
- **Folktandvården in Region Stockholm signs a framework agreement with Medclair**
  Medclair has been awarded a framework agreement following the procurement of equipment for nitrous oxide destruction and monitoring of staff exposure to Folktandvården in Region Stockholm. The procurement supports Folktandvården's work towards Region Stockholm's goal of climate neutrality by 2030. At the same time, it strengthens Medclair's position within public dental care and serves as an important reference for future procurements.

Significant events after the end of the reporting period

- **Medclair adds a new recycling customer in France**
  Medclair has received an order from another customer in the recycling sector in France, in the Île-de-France region. The order value amounts to over SEK 3 million and covers an integrated solution for the measurement, monitoring, and destruction of nitrous oxide, including a service agreement. The contract also includes an option for further deliveries.
- **SUEZ highlights Medclair's technology in French project**
  On 1 July, Medclair's industrial system for the collection and destruction of nitrous oxide into nitrogen and oxygen was presented in collaboration with SUEZ, one of the world's leading players in water and waste management with a presence in 40 countries.
  The workshop gathered regional authorities, government representatives, industry stakeholders, and the media, where the companies demonstrated the solution for the safe and sustainable management of nitrous oxide.
- **Medclair clarifies framework agreement with Folktandvården – contract value 6 MSEK**
  Medclair hereby provides a clarification of the information published on June 30 regarding the framework agreement with Folktandvården in Region Stockholm. The value of the framework agreement amounts to 6 MSEK and the contract period is two years.
- **Medclair merges subsidiary and updates patent valuation – expected to generate a positive one-off effect of approximately MSEK 30**
  Medclair AB has, as part of the company's ongoing efficiency efforts, decided to merge its wholly-owned subsidiary Medclair Sweden AB with the parent company. The merger is expected to be fully completed during the fourth quarter.
- **Medclair secures exclusive framework agreement with French purchasing center Resah**
  Medclair has, through its distributor, won a prestigious framework agreement and been appointed as the sole supplier of equipment for safe nitrous oxide management in a comprehensive national procurement by Resah (Réseau des Acheteurs Hospitaliers) – one of France's absolute largest and most important purchasing centers for public healthcare. The agreement marks an exceptional commercial breakthrough in one of the company's most important core markets.
- **Medclair expands internationally - Singapore and New Zealand**
  Medclair continues to grow internationally through the company's first commercial deals in both Singapore and New Zealand. The establishment on two new continents confirms the strong global demand for sustainable nitrous oxide management and proves the scalability of Medclair's partner-driven business model.

Strong order intake paves the way for continued growth

The second quarter was characterized by a strong order intake of MSEK 25.1 (12.7), while net sales decreased slightly to MSEK 14.3 (15.8) compared to the corresponding quarter of the previous year. In Medclair's business model, where larger installations are delivered over time, variations between individual quarters are natural and primarily reflect the timing of deliveries and revenue recognition, rather than a change in underlying demand.

Order intake therefore provides a better picture of the underlying business development and future sales than a single quarter's net sales, as illustrated in the graph to the right.

Over the past year, we have taken important steps in the development of Medclair's commercial model. By building our own sales organization in our priority markets, we have come closer to our customers, which has resulted in a more even and predictable order flow, while our strategic partners continue to contribute to our market presence and the development of larger business opportunities.

EBITDA for the half-year amounted to MSEK 6.3 (10.0) and profit after tax to MSEK 3.3 (6.5), reflecting deliberate investments in our international expansion. The core business's strong gross margins enable us to self-finance this growth, with investments primarily directed towards commercial scale-up, patent protection, and our new product platform.

The strong order intake during the first half of the year, combined with a positive start to the third quarter, provides us with favorable conditions for the rest of the year. Against this background, we expect full-year sales, in line with the company's plan, to exceed the 2025 level by a good margin.

Positive momentum in the business

Today, Medclair stands on a broader foundation than before. We operate in three business areas – healthcare, dental, and industry – and have built a growing international presence, established in over 20 countries, including installations at more than 150 hospitals. The broader business creates a more diversified revenue base and reduces dependence on individual markets or customer segments. Together with strategic partnerships, this creates favorable conditions for long-term growth.

During the quarter, we continued to develop our business in established markets through new deals, strategic collaborations, and strengthened customer relationships. The framework agreements

Commercial momentum and Book-to-Bill Ratio per quarter (KSEK)



By building our own sales organization in our priority markets, we have come closer to our customers, which has resulted in a more even and predictable order flow

with Resah in France and Folktandvården in Region Stockholm are examples of how we are strengthening our position in healthcare and dental.

Within the recycling segment, we continue to develop collaborations with both leading international players, such as SUEZ and Veolia, and municipal recycling companies. The fact that some of the industry's largest players choose Medclair's solutions strengthens our market position and confirms the quality of our offering. With an established presence in seven European markets, we now also see increased opportunities for upselling and capacity expansion among existing customers.

In parallel, our international expansion continued through the first installations in Singapore and New Zealand. This demonstrates that Medclair is not only deepening its business in established markets but also successfully establishing itself in new geographical markets.

A broader offering for long-term growth

We continue to build a broader and more comprehensive offering within safe and sustainable nitrous oxide management. Through investments in new technology, complementary products, and services, we are strengthening our position as a full-service provider and creating increased customer value. This development entails a more extensive customer offering where we can minimize nitrous oxide leakage throughout the entire usage chain – from increased control during use and an improved mask with increased collection of nitrous oxide, to filter solutions adapted for both operations with a low frequency of use and industrial applications with high flows and low concentrations. With a broader range of products, accessories, and advanced system solutions, we are creating new opportunities for upselling, more recurring business, and long-term customer relationships.

During the period, the merger between the parent company and the wholly-owned subsidiary was also initiated. This simplifies the Group structure, strengthens transparency, and creates a more efficient organization ahead of the next growth phase. The merger is expected to be completed during the fourth quarter.

The strong demand we are seeing in our markets, combined with an established international network and partnerships with some of the industry's leading players, provides Medclair with a solid platform for continued expansion. We enter the autumn with renewed strength – ready to translate this momentum into increased sales, more recurring revenues, and long-term value creation for our shareholders.

Jonas Lundh, CEO

Outlook for the group

The long-term market conditions for Medclair are assessed to remain favorable. Climate and working environment issues are receiving increasing focus in both healthcare and industry, while regulatory requirements and heightened sustainability ambitions are driving demand for solutions for safe and sustainable nitrous oxide management.

With its own sales organization, strategic partnerships, and a growing international presence, Medclair continues to develop its position in priority markets. The company assesses that this development, together with a growing installed customer base and a stronger order book, creates favorable conditions for continued sales growth.

At the same time, work continues on developing a broader offering within safe and sustainable nitrous oxide management. Through complementary products and technical solutions, Medclair is broadening its customer offering, strengthening its position as a full-service provider, and creating conditions for more recurring business through service, aftermarket, and complementary services.

Medclair also continues to develop its business in both established and new geographical markets. The international expansion, together with increased opportunities for upselling and capacity expansion among existing customers, creates further potential for long-term growth.

Medclair is still in an early stage of its commercial journey. With a strong order intake, a growing installed customer base, and a broader international presence, there are favorable conditions to, over time, realize the full potential of the company's technology – a potential that today is assessed to far exceed current revenue levels.

Risks and uncertainties

- The Group holds a number of key patents. This entails a risk of infringement by other parties, which could lead to lengthy and costly legal disputes.
- The uncertain global environment may entail risks related to the supply of raw materials, purchase prices, currency fluctuations (EUR/USD), as well as longer decision-making cycles among public healthcare customers.
- Unwanted staff turnover may lead to disruptions in planned activities.
- In the event of production disruptions at suppliers, delays, or delivery failures, the company may be negatively impacted.

Financial performance and position

The Group

The Group's income statement for the period January – June 2026 includes results from the parent company Medclair AB and the subsidiary Medclair Sweden AB. The comparative period is January – June 2025.

Order intake

Order intake during the first half of the year amounted to MSEK 41.2 (34.7), corresponding to an increase of 18.7%. For the second quarter, order intake amounted to MSEK 25.1 (12.7), a growth of 97.6% compared to the corresponding period of the previous year. The strong order intake is driven by solid demand within the traditional healthcare sector, in combination with additional orders from new customer groups within recycling and industry. The establishment within the recycling segment broadens the company's customer base and offsets the long decision-making cycles within healthcare, and creates conditions for a more linear commercial growth.

Revenue and results

Net sales for the first half of the year amounted to MSEK 32.5 (MSEK 31.4), of which the second quarter accounted for MSEK 14.3 (MSEK 15.8). The business mix is developing positively as the company establishes itself in new industrial applications with shorter sales cycles, which complements the long-term recurring business within the global healthcare sector.

Profit before depreciation (EBITDA) for the half-year amounted to MSEK 6.3 (10.0) and profit after tax to MSEK 3.3 (6.5), reflecting the planned investments in Medclair's continued international expansion. The core business continues to show strong gross margins, which provides us with the capacity to finance the aggressive expansion with our own earnings. The increased cost base is a deliberate part of the strategy to scale up the commercial organization, strengthen our presence in priority growth markets, and build capacity for continued global growth. During the period, investments have been made in, among other things, our own sales resources, key competencies, marketing and exhibition activities, as well as global patent protection and the next-generation product platform.

Investments and depreciation

The Group's investments in tangible and intangible fixed assets during the half-year amounted to MSEK 3.2 (2.7). Of this, MSEK 2.55 (1.85) consists of capitalized work for own account, which relates to strategic development investments in the company's patented product portfolio, including the development of the next-generation technology platform as well as adaptations for industrial applications and the US market. Depreciation and amortization of fixed assets amounted to MSEK -2.6 (-2.6).

Assets
The Group's fixed assets as of June 30, 2026, amounted to MSEK 40.0 (39.6). Approximately MSEK 15.8 (19.4) consists of goodwill attributable to the acquisition of Medclair Sweden AB.

Other intangible assets consist of capitalized development costs of MSEK 16.3 (11.9) and patents related to product development of MSEK 2.6 (2.5).

The Group's current assets, excluding cash, amounted to MSEK 33.5 (23.5).

Equity
At the beginning of the financial year, the Group's equity amounted to MSEK 53.7 (49.0) and at the end of the second quarter, the company's equity amounted to MSEK 78.7 (55.5). The increase in capital is explained by the profit for the period and the directed share issue carried out during the first quarter, which provided the company with net proceeds of MSEK 21.7. The equity ratio amounted to 85% (86%). At the most recent year-end, the share capital was SEK 8,249,206, divided into 82,492,057 shares, each with a quota value of SEK 0,10.

Cash flow and financial position
Cash flow from operating activities before changes in working capital for the half-year amounted to MSEK 5.9 (MSEK 8.9) and for the second quarter to MSEK 0.9 (MSEK 3.8). Operating cash flow after changes in working capital for the half-year amounted to MSEK -5.3 (MSEK 0.3), which is explained by a temporary tie-up of capital in trade receivables and inventory as a result of high delivery volumes towards the end of the period.

The Group's cash and cash equivalents at the end of the period amounted to MSEK 18.9 (MSEK 1.3 as of June 30, 2025, and MSEK 5.7 as of December 31, 2025). The financial preparedness is very strong; the current ratio has strengthened significantly and amounts to 384% (283% as of June 30, 2025), which means that current assets cover current liabilities almost four times over.

Parent company
The Parent Company's net sales for January–June amounted to MSEK 0.0 (0.0). Operating profit amounted to MSEK -1.0 (-0.7). Profit for the period amounted to MSEK -0.9 (-0.5). The company's equity ratio amounted to 100% (99%). The company's cash and cash equivalents at the end of the half-year amounted to MSEK 14.5 (0.9).

Note
This information is such that Medclair AB is obliged to disclose under the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the CEO, on August 20, 2026, at 08:00 CEST.

This report has not been subject to review by the company's auditors.

Stockholm, August 20, 2026

Medclair AB
Jonas Lundh, CEO

For further information, please contact:
Jonas Lundh, CEO, Medclair AB
Phone: +46 76 193 90 90
Email: jonas.lundh@medclair.com

Accounting principles
This report has been prepared in accordance with the Swedish Annual Accounts Act (ÅRL) and BFNAR 2012:1 (K3). The accounting principles applied are the same as those used in the most recent annual report.

MEDCLAIR'S CLIMATE BENEFIT

623,000 tonnes of CO2

Climate benefit from Medclair's delivered equipment for the collection of nitrous oxide (N2O), which would otherwise leak into the atmosphere

Medclair's climate benefit

623,000 tonnes of CO2

City of Stockholm, total emissions 2023

~1.49 million tonnes CO2e



Source: The Environment Barometer, City of Stockholm - 1.5 tonnes CO2e/inhabitant (2023, transport, energy use and waste) × approx. 990,000 inhabitants.

MEDCLAIR'S CLIMATE BENEFIT

Cumulative climate benefit, tonnes CO2e

Latest quarter (Q2 2026)

623,000 tonnes



Source: Medclair AB, interim reports Q3 2024 – Q2 2026 (the box "Medclair's contribution to the global climate benefit"). The figures refer to the cumulative capacity to eliminate CO2e emissions via the company's delivered equipment, not quarterly new additions.

MEDCLAIR'S CLIMATE BENEFIT IN PERSPECTIVE

Compared to Swedish cities' total CO2 emissions



Source Cities: City of Malmö (The Environment Barometer, territorial emissions 2023, calculated from 2.31 tonnes CO2e/inhabitant × approx. 368,000 inhabitants); City of Stockholm (Environment Barometer, 1.5 tonnes CO2e/inhabitant 2023 × approx. 990,000 inhabitants, transport/energy/waste).

The Group's income statement

TSEK	Apr–June 2026	Apr–June 2025	Jan–June 2026	Jan–June 2025	Jan-Dec 2025
Net sales	14,280	15,835	32,518	31,467	52,084
Own work capitalized	1,468	892	2,549	1,848	3,981
Other operating income	351	59	454	158	517
Goods for resale	-4,623	-4,999	-10,840	-9,594	-18,024
Other external costs	-5,115	-3,916	-8,842	-7,509	-13,774
Personnel costs	-5,232	-3,521	-9,568	-6,341	-13,613
EBITDA	**1,129**	**4,350**	**6,271**	**10,029**	**11,171**
Amortization, depreciation and impairment of tangible and intangible fixed assets	-1,282	-1,330	-2,573	-2,578	-5,005
Other operating expenses	-250	-55	-324	-520	-1,028
OPERATING PROFIT	**-403**	**2,965**	**3,374**	**6,931**	**5,138**
Financial items	-32	-421	-53	-436	-485
Income Tax	-	-	-	-	-
NET PROFIT FOR THE PERIOD	**-435**	**2,544**	**3,321**	**6,495**	**4,653**

The Group's balance sheet

TSEK	30 June 2026	30 June 2025	31 Dec 2025
Non-current assets			
Intangible non-current assets	34,679	33,740	33,817
Tangible non-current assets	5,217	5,813	5,448
Financial non-current assets	126	-	-
Total non-current assets	**40,022**	**39,553**	**39,265**
Current assets			
Inventories, etc.	7,653	7,391	5,946
Accounts receivable	12,715	5,049	4,118
Current tax receivables	-	164	29
Other receivables	828	3,300	1,560
Prepaid expenses and accrued income	12,275	7,614	4,020
Cash and bank	18,870	1,256	5,739
Total current assets	**52,341**	**24,774**	**21,412**
Total assets	**92,363**	**64,327**	**60,677**
Equity	**78,734**	**55,529**	**53,686**
Current liabilities			
Advances from customers	1,612	-	-
Accounts payable	5,054	4,552	3,198
Current tax liabilities	7	-	-
Other liabilities	662	231	1,429
Accrued expenses and deferred income	6,294	4,015	2,364
Total current liabilities	**13,629**	**8,798**	**6,991**
Total equity and liabilities	**92,363**	**64,327**	**60,677**

The Group's equity

TSEK	30 June 2026	30 June 2025	31 Dec 2025
Opening equity	53,686	49,034	49,034
Share issue	21,727	-	-
Changes in group structure	-	-	-
Net profit for the period	3,321	6,495	4,653
Total equity	**78,734**	**55,529**	**53,686**

The Group's cash flow

	Apr–June		Jan–June		Jan-Dec
TSEK	2026	2025	2026	2025	2025
PROFIT AFTER FINANCIAL ITEMS	-435	2,544	3,321	6,495	4,653
Adjustment for non-cash items	1,309	1,222	2,609	2,422	5,062
Cash flow before changes in working capital	**874**	**3,766**	**5,930**	**8,917**	**9,715**
Change in working capital	-480	-5,915	-11,196	-8,620	-2,717
Cash flow from operating activities	**394**	**-2,149**	**-5,266**	**297**	**6,998**
Investing activities	**-1,896**	**-154**	**-3,330**	**-1,624**	**-3,842**
Financing activities	**-**	**-**	**21,727**	**-**	**-**
Total cash flow	**-1,502**	**-2,303**	**13,131**	**-1,327**	**3,156**
Cash and cash equivalents at the beginning of the period	20,372	3,559	5,739	2,583	2,583
Cash and cash equivalents at the end of the period	**18,870**	**1,256**	**18,870**	**1,256**	**5,739**

Parent company income statement

	Apr–June		Jan–June		Jan-Dec
TSEK	**2026**	**2025**	**2026**	**2025**	**2025**
Other operating income	10	7	26	22	51
Other external expenses	-424	-192	-626	-333	-806
Personnel costs	-182	-179	-360	-358	-713
Operating profit before depreciation and financial items	**-596**	**-364**	**-960**	**-669**	**-1,468**
Other operating expenses	-	-	-	-	-
Operating profit	**-596**	**-364**	**-960**	**-669**	**-1,468**
Financial items	4	106	14	139	256
Income tax	-	-	-	-	-
Net profit for the period	**-592**	**-258**	**-946**	**-530**	**-1,212**

Parent company balance sheet

TSEK	**30 June 2026**	**30 June 2025**	**31 Dec 2025**
Non-current assets			
Shares in group companies	46,504	46,504	46,504
Financial non-current assets	-	-	-
Total non-current assets	**46,504**	**46,504**	**46,504**
Current assets			
Receivables from group companies	25,382	16,667	16,167
Current tax assets	19	28	-
Other receivables	130	2,205	1,317
Prepaid expenses and accrued income	43	119	74
Cash and bank balances	14,498	889	1,637
Total current assets	**40,072**	**19,908**	**19,195**
Total assets	**86,576**	**66,412**	**65,699**
Equity	**86,251**	**66,152**	**65,470**
Current liabilities			
Liabilities to credit institutions	-	-	-
Accounts payable	63	-	-
Other liabilities	-	4	-
Accrued expenses and deferred income	262	256	229
Total current liabilities	**325**	**260**	**229**
Total equity and liabilities	**86,576**	**66,412**	**65,699**

Parent company equity

TSEK	30 Jun 2026	30 Jun 2025	31 Dec 2025
Opening Equity	65,470	66,682	66,682
New share issue	21,727	-	-
Profit for the period	-946	-530	-1,212
Total equity	**86,251**	**66,152**	**65,470**

Parent company cash flow

	Apr–Jun		Jan–Jun		Jan-Dec
TSEK	2026	2025	2026	2025	2025
PROFIT AFTER FINANCIAL ITEMS	-592	-257	-946	-530	-1,212
Non-cash items	-	-3	-	-28	-
Cash flow before changes in working capital	**-592**	**-260**	**-946**	**-558**	**-1,212**
Changes in working capital	-4,728	-600	-7,920	-1,847	-445
Cash flow from operating activities	**-5,320**	**-860**	**-8,866**	**-2,405**	**-1,657**
Investing activities	**-**	**1,055**	**-**	**1,055**	**1,055**
Financing activities	**-**	**-**	**21,727**	**-**	**-**
Total cash flow	**-5,320**	**195**	**12,861**	**-1,350**	**-602**
Cash and cash equivalents at the beginning of the period	19,818	694	1,637	2,239	2,239
Cash and cash equivalents at the end of the period	**14,498**	**889**	**14,498**	**889**	**1,637**

Glossary: Key Financial Indicators & Definitions

Net sales
Operating revenue from goods sold and services provided during the period, net of discounts and VAT.

EBITDA
Operating profit before depreciation, amortization, impairment, and financial items. Measures operational profitability.

Equity ratio (%)
Equity expressed as a percentage of total assets at the end of the period. Indicates the company's long-term financial stability.

Quick ratio / Current ratio (%)
Current assets divided by current liabilities, expressed as a percentage. Measures the company's ability to meet short-term obligations.

Cash flow
The net change in cash and cash equivalents during the period, comprising operating, investing, and financing activities.

Number of shares at end of period
Total number of registered and outstanding shares on the balance sheet date.

Earnings per share
Profit or loss for the period divided by the weighted average number of shares outstanding during the period.

Order intake
The total monetary value of all received and confirmed customer orders during the period. Indicates underlying market demand and future revenue growth.

Book-to-Bill Ratio
The ratio of order intake to net sales during the period (Order intake / Net sales). A ratio above 1.0 indicates that demand exceeds current deliveries, signaling business expansion.

Equity and shareholder structure

Equity

At the beginning of the financial year, the Group's equity amounted to 53.7 MSEK (49.0). At the end of the second quarter, equity amounted to 78.7 MSEK (55.5). The increase in equity is explained by the profit for the period as well as the directed share issue carried out during the first quarter, which provided the company with a net of 21.7 MSEK. The equity ratio amounted to 85 percent (86).

Share capital and number of shares

At the end of the previous financial year, the share capital amounted to 8,249,206 SEK, divided into 82,492,057 shares, each with a quota value of 0.10 SEK. Following the completed directed share issue, the share capital amounts to 9,164,706 SEK, divided into 91,647,057 shares, each with a quota value of 0.10 SEK.

Warrants and employee stock option programs

As of June 30, 2026, the company had no outstanding warrants or employee stock option programs.

Ownership structure

2026-06-30	Shares	%
Eiffel Investment Group	10,047,000	10.98%
Bäck Family*	8,000,000	8.75%
AVANZA Pension	8,000,000	8.75%
Familjen Johansson	5,800,000	6.34%
Nordnet Pension	5,133,000	5.61%
Piroska Forkman	3,491,000	3.82%
Baljeu Family	2,806,000	3.07%
Mikael König*	2,600,000	2.84%
Jerker Sundling	2,019,522	2.21%
Peter Håkansson	1,295,000	1.42%
Szabo Family	949,000	1.04%
Other shareholders	41,323,375	45.18%
	91,463,897	**89.02%**

The proportion of shares held via Nordnet and Avanza is relatively high, as some shareholders own shares through pension solutions.

* The holding is estimated.

Upcoming reporting dates

Interim report Q3 2026	5 November 2026

Corporate Identity Number: 556691-3728

Medclair is a member of Swecare and Nordic Centre for Sustainable Healthcare.

www.medclair.com

FOLLOW US ON